Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Davis
• Treatments: Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

• patients with a clinical diagnosis of laryngopharyngeal reflux diagnosed by any combination of patient symptoms, physical/endoscopic findings, and 24 hr dual-probe ambulatory pH-testing.

• 18 years of age or older

Exclusion Criteria:

• patients with life-threatening complications of laryngeal, pharyngeal or esophageal cancer, subglottic or tracheal stenosis, laryngeal papilloma, airway compromise

• elite vocal performs with LPR-related dysphonia

• under 18 years of age

• pregnant and/or lactating women

• persons with known hypersensitivity to any component of the formulation

• patients taking theophylline, ketoconazole, ampicillin or digoxin

• persons with hepatic and renal insufficiency